Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline and Epix Pharmaceuticals have entered a collaboration to discover and market medicines targeting four G-protein coupled receptors for the treatment of a variety of diseases.
Subscribe to our email newsletter
The agreement will include including Epix's novel 5-HT4 partial agonist program, PRX-03140, in early-stage clinical development for the treatment of Alzheimer's disease. The alliance will be conducted through GSK's Center of Excellence for External Drug Discovery.
Epix will receive total initial payments of $35 million, including $17.5 million through the purchase of shares of common stock. In addition, Epix will be eligible to earn potential milestones of up to $1.2 billion. Epix will also receive tiered double-digit royalties on sales by GSK of all collaboration-developed product sales.
“This alliance will provide us with access to significant capital in the near and long term to support the ongoing development of PRX-03140 and three additional programs, as well as the ability to continue to move forward our existing programs. Furthermore, the co-promotion option in this collaboration provides further opportunity for Epix to build a sales force in the future,” stated Michael Kauffman, CEO of Epix.